secwatch.observer — SEC 8-K summary
======================================

Issuer:     RF Acquisition Corp II (RFAI)
CIK:        0002012807
Form:       8-K
Filed at:   2025-10-02T23:59:59+00:00
Accession:  0001829126-25-007836
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RF Acquisition Corp II to merge with Nanyang Biologics in $1.5B SPAC deal; NYB to list on Nasdaq
--------------------------------------------------------------------------------

- Business Combination Agreement signed Oct 2, 2025; RFAC II will merge into PubCo, then amalgamate with Nanyang.
- Implied enterprise value of $1.5 billion for Nanyang Biologics, an AI drug discovery platform.
- Flagship asset NB-A002 targets DDR cancers via previously undruggable ILF2; proprietary AI model DTIGN.
- Combined company to list on Nasdaq under reserved ticker "NYB"; board to have 7 directors, 6 designated by Nanyang.
- Support agreements secured with 75%+ Nanyang shareholders and founder Alfa 24; lock-up up to 24 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2012807/000182912625007836/0001829126-25-007836-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2012807/000182912625007836/rfacquisition2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001829126-25-007836

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer